Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12344
Title: Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.
Authors: Simpson, Richard W;Nicholson, Geoffrey C;Proietto, Joseph;Sarah, Alana;Sanders, Kerrie M;Phillips, Gabrielle;Chambers, Jo;MacGinley, Rob;Orford, Neil;Walder, Ken;Krippner, Guy;Skoff, Kathy;Wacher, Vincent J
Affiliation: Box Hill Hospital, Box Hill, Victoria, Australia.
Department of Clinical and Biomedical Sciences, Geelong Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Heidelberg Repatriation Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Clinical Trial Unit, Department of Medicine, Barwon Health, Geelong, Victoria, Australia.
Deakin University, Geelong, Victoria, Australia.
Department of Epidemiology and Preventive Medicine, Barwon Health/Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia.
Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia. vwacher@vervapharma.com.
Issue Date: 14-Aug-2014
Citation: Diabetes Care 2014; 37(11): 3121-3
Abstract: To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes.This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (ΔHbA1c).Mean ± SD baseline HbA1c was 7.1 ± 0.7% (54 ± 5 mmol/mol; n = 37) and 7.4 ± 0.6% (57 ± 5 mmol/mol; n = 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a ΔHbA1c of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [-9.0, 0.4]), an increase in the proportion of patients achieving HbA1c ≤6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients.Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.
Internal ID Number: 25125506
URI: http://ahro.austin.org.au/austinjspui/handle/1/12344
DOI: 10.2337/dc14-1038
URL: http://www.ncbi.nlm.nih.gov/pubmed/25125506
Type: Journal Article
Subjects: Aged
Carbonic Anhydrase Inhibitors.adverse effects.therapeutic use
Diabetes Mellitus, Type 2.drug therapy
Double-Blind Method
Female
Hemoglobin A, Glycosylated.analysis
Humans
Hypoglycemic Agents.therapeutic use
Male
Metformin.therapeutic use
Methazolamide.adverse effects.therapeutic use
Middle Aged
Weight Loss.drug effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.